trial · primary record
Abenacianine
Lung Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 132 |
| Primary completion | 2027-03 |
| Primary endpoint | Identify the proportion of participants with at least one Clinically Significant Event (CSE) as defined by: |
| Registry ID | NCT07499674 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:37.398Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07499674
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.